IMDX (Insight Molecular Diagnostics) Beneish M-Score: -5.85 (As of Jun. 25, 2026)


IMDX Insight Molecular Diagnostics Inc IMDX
49 GF Score
Price $5.42
GF Value $1.26
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Insight Molecular Diagnostics Beneish M-Score?

Insight Molecular Diagnostics IMDX -0.19% 49 Beneish M-Score is -5.85 as of Jun. 25, 2026. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.26 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Insight Molecular Diagnostics ranks better than 96.41% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -5.85 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Insight Molecular Diagnostics's Beneish M-Score or its related term are showing as below:

IMDX' s Beneish M-Score Range Over the Past 10 Years
Min: -21.78   Med: -0.05   Max: 155.37
Current: -5.85

During the past 13 years, the highest Beneish M-Score of Insight Molecular Diagnostics was 155.37. The lowest was -21.78. And the median was -0.05.


Insight Molecular Diagnostics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Insight Molecular Diagnostics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insight Molecular Diagnostics Beneish M-Score Chart

Insight Molecular Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 -21.78 -3.15 -1.72 -4.36

Insight Molecular Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.96 0.05 0.29 -4.36 -5.85

IMDX vs BDSX, XGN, FONR: Beneish M-Score Comparison

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insight Molecular Diagnostics Beneish M-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's Beneish M-Score falls into.


IMDX
49GF Score
Insight Molecular Diagnostics Inc IMDX
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insight Molecular Diagnostics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Insight Molecular Diagnostics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.0874+0.528 * 1.0245+0.404 * 0.088+0.892 * 0.5072+0.115 * 0.9328
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 2.3305+4.679 * -0.27311-0.327 * 1.6905
=-5.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $0.16 Mil.
Revenue was 0.032 + 1.139 + 0.26 + 0.518 = $1.95 Mil.
Gross Profit was 0.015 + 0.496 + 0.139 + 0.35 = $1.00 Mil.
Total Current Assets was $30.52 Mil.
Total Assets was $40.43 Mil.
Property, Plant and Equipment(Net PPE) was $8.91 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.34 Mil.
Selling, General, & Admin. Expense(SGA) was $17.04 Mil.
Total Current Liabilities was $12.01 Mil.
Long-Term Debt & Capital Lease Obligation was $1.31 Mil.
Net Income was -4.29 + -22.955 + -10.854 + -9.742 = $-47.84 Mil.
Non Operating Income was 6.064 + -12.979 + -3.155 + -2.746 = $-12.82 Mil.
Cash Flow from Operations was -7.639 + -5.545 + -4.502 + -6.298 = $-23.98 Mil.
Total Receivables was $3.54 Mil.
Revenue was 2.138 + 1.486 + 0.115 + 0.104 = $3.84 Mil.
Gross Profit was 1.325 + 0.595 + 0.05 + 0.05 = $2.02 Mil.
Total Current Assets was $36.26 Mil.
Total Assets was $60.36 Mil.
Property, Plant and Equipment(Net PPE) was $7.16 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.72 Mil.
Selling, General, & Admin. Expense(SGA) was $14.42 Mil.
Total Current Liabilities was $9.68 Mil.
Long-Term Debt & Capital Lease Obligation was $2.07 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.157 / 1.949) / (3.54 / 3.843)
=0.080554 / 0.921155
=0.0874

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2.02 / 3.843) / (1 / 1.949)
=0.525631 / 0.513084
=1.0245

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (30.517 + 8.911) / 40.427) / (1 - (36.263 + 7.155) / 60.36)
=0.024711 / 0.280683
=0.088

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1.949 / 3.843
=0.5072

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.72 / (1.72 + 7.155)) / (2.337 / (2.337 + 8.911))
=0.193803 / 0.20777
=0.9328

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(17.04 / 1.949) / (14.417 / 3.843)
=8.742945 / 3.751496
=2.3305

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.307 + 12.005) / 40.427) / ((2.074 + 9.683) / 60.36)
=0.329285 / 0.194781
=1.6905

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-47.841 - -12.816 - -23.984) / 40.427
=-0.27311

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Insight Molecular Diagnostics has a M-score of -5.85 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -5.85 mean?
Insight Molecular Diagnostics (IMDX) has a Beneish M-Score of -5.85 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Insight Molecular Diagnostics and its competitors. According to the industry distribution chart, Insight Molecular Diagnostics ranks #7 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 3.6%.
Is Insight Molecular Diagnostics' Beneish M-Score too high?
Insight Molecular Diagnostics' current Beneish M-Score is -5.85. Based on the distribution chart, Insight Molecular Diagnostics ranks #7 out of 195 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Beneish M-Score compare to BDSX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #7 out of 195 companies for Beneish M-Score. This places Insight Molecular Diagnostics in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Diagnostics & Research company?
A good Beneish M-Score depends on the Medical Diagnostics & Research industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Insight Molecular Diagnostics and its competitors. Insight Molecular Diagnostics's current Beneish M-Score is -5.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.26, compared to a current price of $5.42 — trading 330.2% above its estimated fair value. The current Beneish M-Score is -5.85. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Beneish M-Score is -5.85 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of $5.42 is trading 330.2% above its estimated GF Value™ of $1.26. GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.

Key valuation signals for IMDX:

  • Beneish M-Score: -5.85
  • GF Value™: $1.26 vs. price of $5.42 (330.2% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insight Molecular Diagnostics Business Description

Other Exchanges 0KCC:UK7OC0:Germany
Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score

Get the complete analysis for IMDX

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.42
Price
$1.26
GF Value